Ondine CEO increases shareholding
CEO and spouse increase shareholding to 35.36% through purchase of 149,225 shares at 12.5p each.
- Shares purchased 149,225
- Price per share 12.5 pence
- Total investment £18,653.13
- CEO and spouse total holding 156,314,029 shares (35.3621%)
Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes
Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that The Pennycook Family Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband of Carolyn Cross, has purchased 149,225 shares ("Common Shares") in the Company at a price of 12.5 pence per Common Share on 03 February 2025.
Following this transaction, Carolyn Cross and Robert Cross, directly and indirectly, hold 156,314,029 Common Shares representing 35.3621% of the issued share capital of the Company.
About Ondine Biomedical Inc.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Carolyn Cross and her PCA |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer (PDMR) |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Ondine Biomedical Inc. |
| b) | LEI | 9845005B69E07CGF4A56 |
| a) | Description of the Financial instrument, type of instrument | Common shares |
| Identification code | ISIN: CA68234M2058 | |
| b) | Nature of the transaction | Share purchase |
| c) | Price(s) and volume(s) | 149,225 shares at 12.5 pence each |
| d) | Aggregated information: ·Aggregated volume ·Price | N/A |
| e) | Date of the transaction | 03 February 2025 |
| f) | Place of the transaction | AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.